OKYO Pharma Ltd.
OKYO
OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases. The company concentrates on ophthalmology and corneal health, with research programs aimed at conditions such as dry eye disease, allergic conjunctivitis, uveitis, and ocular pain. Its pipeline includes urcosimod, an investigational candidate being studied for multiple eye-related indications, and OK-201, another development-stage therapy for ocular pain. OKYO Pharma Ltd. operates as a research and development business in the healthcare sector, targeting unmet needs in diseases affecting the cornea and anterior segment of the eye. Based in London and incorporated in Guernsey, the company plays a specialized role in the biopharmaceutical market by advancing non-opioid and non-steroidal treatment approaches for complex eye disorders.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$9M
▼ -90.2% YoY
Op. Margin
–
ROIC
-108.87%
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▼ -227.9% YoY
Op. Cash Flow (TTM)
-$6M
▼ -227.8% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$21M
Continue Research
Peers
Biotechnology · Pick stocks to compare with OKYO
OKYO Pharma (OKYO) in three numbers
Questions about OKYO Pharma
Is OKYO Pharma a high-quality business?
OKYO Pharma scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$21M, and its weakest is return on capital at -108.9%. The Quality tab shows every check against its target.
Does OKYO Pharma (OKYO) pay a dividend?
No. OKYO Pharma (OKYO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing OKYO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.